BAIT
TOP3A
TOP3, ZGRF7
topoisomerase (DNA) III alpha
GO Process (2)
GO Function (2)
GO Component (2)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Homo sapiens
PREY
CDC73
C1orf28, FIHP, HPTJT, HRPT1, HRPT2, HYX
cell division cycle 73
GO Process (17)
GO Function (2)
GO Component (2)
Gene Ontology Biological Process
- cellular response to lipopolysaccharide [ISS]
- endodermal cell fate commitment [ISS]
- histone H2B ubiquitination [IDA]
- histone monoubiquitination [IDA]
- mRNA polyadenylation [IMP]
- negative regulation of G1/S transition of mitotic cell cycle [IDA]
- negative regulation of cell proliferation [IDA]
- negative regulation of epithelial cell proliferation [IMP]
- negative regulation of fibroblast proliferation [IMP]
- negative regulation of myeloid cell differentiation [IDA]
- negative regulation of transcription from RNA polymerase II promoter [IMP]
- positive regulation of Wnt signaling pathway [IDA]
- positive regulation of mRNA 3'-end processing [IMP]
- positive regulation of transcription elongation from RNA polymerase II promoter [IDA]
- positive regulation of transcription from RNA polymerase II promoter [IDA]
- protein destabilization [IMP]
- stem cell maintenance [ISS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Synthetic Lethality
A genetic interaction is inferred when mutations or deletions in separate genes, each of which alone causes a minimal phenotype, result in lethality when combined in the same cell under a given condition.
Publication
A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.
An emerging therapeutic strategy for cancer is to induce selective lethality in a tumor by exploiting interactions between its driving mutations and specific drug targets. Here we use a multi-species approach to develop a resource of synthetic lethal interactions relevant to cancer therapy. First, we screen in yeast ∼169,000 potential interactions among orthologs of human tumor suppressor genes (TSG) and ... [more]
Mol. Cell Aug. 04, 2016; 63(3);514-25 [Pubmed: 27453043]
Throughput
- High Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507) [hela cell (BTO:0000567)]
Additional Notes
- Chemo-genetic screen with siRNAs
- Drug target: TOP1,TOP2A,TOP3A triple mutant
- Drug: irinotecan
- HeLa cervical cancer cell line
Curated By
- BioGRID